These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30187553)

  • 1. On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors.
    Parkes M
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():5-6. PubMed ID: 30187553
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Švegl P; Rajar P; Hanžel J; Koželj M; Novak G; Smrekar N; Ferkolj I; Štabuc B
    Aliment Pharmacol Ther; 2019 Apr; 49(7):880-889. PubMed ID: 30784100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Doses of Azathioprine are Effective in Combination With Infliximab in Inflammatory Bowel Disease but May not be During Induction Therapy.
    Roblin X; Flourié B; Paul S
    J Crohns Colitis; 2018 Apr; 12(5):628. PubMed ID: 29360962
    [No Abstract]   [Full Text] [Related]  

  • 4. Pediatric inflammatory bowel disease.
    Orenstein SR
    Curr Gastroenterol Rep; 1999 Jun; 1(3):220-2. PubMed ID: 10980953
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalized medicine: inevitable.
    Peña AS
    Rev Esp Enferm Dig; 2010 Oct; 102(10):573-6. PubMed ID: 21039064
    [No Abstract]   [Full Text] [Related]  

  • 6. What are the treatment targets in inflammatory bowel disease (IBD) in 2020?: Session one summary.
    Sparrow M
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():4-5. PubMed ID: 33817846
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pretreatment screening for inflammatory bowel diseases;significance and problems in genotyping of NUDT15].
    Kakuta Y; Kinouchi Y; Masamune A
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(3):195-207. PubMed ID: 32161240
    [No Abstract]   [Full Text] [Related]  

  • 8. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent.
    Polakovicova V; Kadleckova B; Lucenicova J; Otottova K; Kinova S; Mikus P; Zelinkova Z
    Dig Liver Dis; 2019 Aug; 51(8):1112-1116. PubMed ID: 31147215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in IBD: genes, drugs, bugs and omics.
    Mao R; Chen M
    Nat Rev Gastroenterol Hepatol; 2022 Feb; 19(2):81-82. PubMed ID: 34785787
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward a personalized medicine approach to the management of inflammatory bowel disease.
    Mosli MH; Sandborn WJ; Kim RB; Khanna R; Al-Judaibi B; Feagan BG
    Am J Gastroenterol; 2014 Jul; 109(7):994-1004. PubMed ID: 24842338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors in inflammatory bowel disease: Looking into the magic ball: Session one summary.
    Begun J
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():4. PubMed ID: 30187557
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patients.
    Parihar V; Maceneaney O; Maguire S; Garry C; O'Sullivan M; Kennedy M; Safaya K; Smyth C; Farrell R
    Ir J Med Sci; 2017 May; 186(2):329-332. PubMed ID: 27241033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is genomic analysis relevant to IBD?
    Chakravarti S
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S81-2. PubMed ID: 18816661
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?
    Lee HS; Cleynen I
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Roblin X; Boschetti G; Williet N; Nancey S; Marotte H; Berger A; Phelip JM; Peyrin-Biroulet L; Colombel JF; Del Tedesco E; Paul S; Flourie B
    Aliment Pharmacol Ther; 2017 Jul; 46(2):142-149. PubMed ID: 28449228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision medicine: how multiomics will shape the future of inflammatory bowel disease?
    Borren NZ; Ananthakrishnan AN
    Curr Opin Gastroenterol; 2022 Jul; 38(4):382-387. PubMed ID: 35762697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine in the treatment of inflammatory bowel diseases.
    Parfenov AI; Knyazev OV; Kagramanova AV; Fadeeva NA
    Ter Arkh; 2018 Feb; 90(2):4-11. PubMed ID: 30701765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease.
    Sutherland LR
    Med Sect Proc; 1990; ():109-23. PubMed ID: 2103941
    [No Abstract]   [Full Text] [Related]  

  • 19. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
    Roberts RL; Gearry RB; Barclay ML
    Pharmacogenomics; 2010 Nov; 11(11):1505-8. PubMed ID: 21121769
    [No Abstract]   [Full Text] [Related]  

  • 20. [Genetic factors affecting elevated thiopurine sensitivity in Japanese patients with inflammatory bowel disease].
    Andoh A; Imaeda H; Osaki R; Ban H
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():639-45. PubMed ID: 23126166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.